Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved indication is for advanced melanoma. Amtagvi is off to a great start after its ...

Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Cardiac sarcoidosis (CS) was a complication in about 10% of pulmonary sarcoidosis (PS) cases, investigators reported in Respiratory Medicine. The retrospective study assessed the prevalence, incidence ...

The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

Animal studies have shown that sepsis induces extensive lymphocyte apoptosis 1,2,3. Patients who die of sepsis and multiple organ failure have lymphocyte apoptosis in the spleen, intestinal lamina ...

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to ...

A new study published in JCI Insight suggests that interleukin-7 (IL-7), a key immune-boosting cytokine, may help critically ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved ...

Cross-sectional studies and Mendelian randomization show that insulin resistance and chronic inflammation mediate the ...

Doctors will measure a person’s lymphocyte levels as part of a complete blood count. In this article, we look at different types of lymphocytes, what healthy levels in the blood are, and what ...